What is IgM/IgG Rapid Test Kits Market Scope?
The Rapid COVID-19 IgM / IgG Combo Test Kit is a lateral flow immunoassay for the purpose of qualitative detection as well as differentiation of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies that work against SARS-CoV-2 in human serum and acid citrate dextrose (ACD) )) Plasma. The global market for corona test kits is growing rapidly due to the global outbreak of the coronavirus. The number of patients in hospitals is growing rapidly and these countries are trying to get access to the test kit to screen every suspect and slow the spread of the virus. BioMedomics' combined IgM-IgG rapid test for COVID-19 is a lateral flow immunoassay that can be used to qualitatively detect IgG and IgM antibodies of the new coronavirus in human serum, plasma, or whole blood in vitro. The test should not be used with heat-inactivated or any other inactivated human specimens such as blood, serum, plasma, etc. Fresh samples should be collected and tested immediately. The combo test kit is usually used for identifying individuals with an adaptive immune response to SARS-CoV-2 who indicate a recent or previous infection. At this point, it is unknown how long antibodies persist after infection and whether the presence of antibodies confers protective immunity. The IgM / IgG Combo Test Kit is not be used for diagnosing acute SARS-CoV-2 infection. The tests are limited to laboratories that are certified according to the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42, USA, 263a, and meet the requirements for performing tests of medium or high complexity. The fast COVID-19 IgM / IgG combination test kit is based on the principle of immunochromatography. Mouse anti-human IgM and human IgG antibodies are immobilized on the nitrocellulose membrane as two individual test lines (IgM line and IgG line) in the test window of the test device. The IgM line in the test window is closer to the sample well, followed by the IgG line. While the test sample flows through the membrane.
The market study is being classified by Type (RDT(Rapid Diagnostic Test), ELISA(Enzyme-linked Immunosorbent Assay) and Neutralization Assay), by Application (Hospital, Special Clinic and Research Institution) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global IgM/IgG Rapid Test Kits market throughout the predicted period.
Cellex (Germany), RayBiotech (United States), Biopanda (United Kingdom), BioMedomics (United States), GenBody(South Korea), SD Biosensor(South Korea), Advaite (United States), Premier Biotech (United States), Epitope Diagnostics (United States), CTK Biotech (United States), Creative Diagnostics (United States), Eagle Biosciences (United States), Sure Biotech (United States), SugenTech Inc. (South Korea), Sensing Self, PTE. Ltd (Singapore), Euroimmun AG (Germany), Liming Bio (China), Beijing Wantai Biological (China) and Livzon Diagnostics (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Shenzhen BioEasy Biotechnology (China), Orient Gene Biotech (China), Innovita Biological Technology Co. Ltd. (China), Dynamiker (Singapore) and Guangzhou Wonfo Biotech (China).
AdvanceMarketAnalytics has segmented the market of Global IgM/IgG Rapid Test Kits market by Type, Application and Region.
On the basis of geography, the market of IgM/IgG Rapid Test Kits has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
“Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) - Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff.” “This policy is intended to remain in effect only for the duration of the public health emergency related to COVID-19 declared by the Secretary of Health and Human Services (HHS) on January 31, 2020, effective January 27, 2020, including any renewals made by the HHS Secretary in accordance with section 319(a)(2) of the Public Health Service Act (PHS Act).”
Influencing Market Trend
- Increasing Number of Investments for Research & Development of IgM/IgG Rapid Test Kits
- Increasing Government and Industry Players Initiatives
- Increasing Number of Laboratory to Check Diseases
- Increasing Demand for Corona Test Kits in Hospitals to Diagnose the Patients with Symptoms
- Increasing Prevalence of Chronic Diseases
- The Opening of Coronavirus Test Centers at Different Parts of Countries Across the World
- The number of patients in the hospitals is increasing rapidly, and the countries are trying to get access to the test kit to inspect each and every suspected person to slow the spread of the virus.
- Lack of WorkForce for Manufacturing of Test Kits
- Stringent Government Policies about the Kits
- Shortage of Corona Test Kits
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, and Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.